[ad_1]
THE WHAT? Bridgepoint fund, Bridgepoint Europe VII has introduced that it has made a strategic funding in RoC Skincare. Below the phrases of the deal RoC’s present backer, Gryphon Traders, will promote its majority stake to Bridgepoint for an undisclosed sum.
THE DETAILS The acquisition is the fund’s sixth builds on Bridgepoint’s rising monitor document of supporting companies within the wider dermatology ecosystem, together with Vivacy and HTL.
THE WHY? Fernando Acosta, CEO of RoC Skincare, mentioned: “With Bridgepoint’s deep experience within the dermatology sector and its robust European presence, RoC is poised to capitalise on the promising development alternatives that lie forward. I want to thank the RoC crew and Gryphon for his or her help over the previous few years. By way of the exhausting work and innovation of RoC’s proficient crew, we’ve grow to be one of many largest unbiased skincare manufacturers globally, whereas upholding our dedication to delivering one of the best clinically confirmed pores and skin well being options.”
[ad_2]
Source_link